Overview of how precision dosing can be incorporated into model-informed drug development (MIDD) to support more informed decision-making and improve development efficiency.

Summary of population pharmacokinetic modeling of rivoceranib in healthy subjects and oncology patients to support dose selection and clinical development strategy.

Population PK/PD analysis of NGM707 in patients with advanced solid tumors demonstrated pharmacokinetics consistent with monoclonal antibodies, with body weight identified as the primary covariate. Model-based receptor occupancy simulations supported dose selection and the design of subsequent clinical studies.

Evaluation of the impact of food and acid-reducing agents on the pharmacokinetics of etrumadenant demonstrated no clinically significant effects, supporting flexible dosing and combination strategies in clinical development.

Population PK analysis of camrelizumab showed consistent exposure across cancer types, supporting fixed dosing. Covariate analysis indicated no clinically meaningful impact on pharmacokinetics, supporting its use in combination therapy for HCC.